Current situation and development trend of CAR-NK anti-tumor research

Chinese Journal of Cancer Biotherapy

Volumn 23, Issue 1, 2016, Pages 1-10

  Yin, Shulei ^a   Yu, Yizhi ^a   Cao, Xuetao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CAR NK; Chimeric antigen receptor (CAR); Hematologic neoplasms; NK 92; Solid tumor; Tumor immunotherapy

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CELL THERAPY; HUMAN; NATURAL KILLER CELL; NONHUMAN;

EID: 84962079893     PISSN: 1007385X     EISSN: None     Source Type: Journal    
DOI: 10.3872/j.issn.1007-385X.2016.01.001     Document Type: Article

References (71)

1. PEGRAM H J, SMITH E L, RAFIQ S, et al. GAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies? [J]. Immunotherapy, 2015, 7 (5): 545-561. DOI: 10. 2217/imt. 15.6.
2. MILLER J S, SOIGNIER Y, PANOSKALTSIS-MORTARI A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer [J]. Blood, 2005, 105(8): 3051-3057. DOI: 10. 1182/blood-2004-07-2974.
3. RUBNITZ J E, INABA H, RIBEIRO R G, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia [J]. J Clin Oncol, 2010,28(6): 955-959. DOI: 10. 1200/ JGO.2009.24.4590.
4. GURTI A, RUGGERI L, DADDIO A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients [J]. Blood, 2011,118(12): 3273-3279. DOI: 10.1182/ blood-2011-01-329508.
5. VIVIER E, RAULET D H, MORETTA A, et al. Innate or adaptive immunity? The example of natural killer cells [J]. Science, 2011,331(6013): 44-49. DOI: 10. 1126/science. 1198687.
6. + and Fas' tumor cells [J]. Blood, 1998, 92(11): 4248-5425. PMID: 9834230.
7. SGREPANTI V, WALLIN R P, LJUNGGREN H G, et al. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells [J]. J Immunol, 2001,167(4): 2068-2073. PMID: 11489989.
8. KAYAGAKI N, YAMAGUGHI N, NAKAYAMA M, et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells [J]. J Immunol, 1999, 163(4): 1906-1913. PMID: 10438925.
9. JONGKER N T, SHIFRIN N, DELEBEGQUE F, et al. Mature natural killer cells reset their responsiveness when exposed to an altered MHG environment [J]. J Exp Med, 2010, 207(10): 2065-2072. DOI: 10. 1084/jem. 20100570.
10. KARRE K. Immunology. A perfect mismatch [J]. Science, 2002, 295 (5562): 2029-2031. DOI: 10. 1126/science. 1070538.
11. CAMPBELL K S, HASEGAWA J. Natural killer cell biology: an update and future directions [J]. J Allergy Clin Immunol, 2013, 132(3): 536-544. DOI: 10. 1016/j. jaci. 2013. 07. 006.
12. GLIENKE W, ESSER R, PRIESNER G, et al. Advantages and applications of CAR-expressing natural killer cells [J]. Front Pharmacol, 2015, 6: 21. DOI: 10. 3389/fphar. 2015. 00021.
13. DOTTI G, GOTTSGHALK S, SAVOLDO B, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells [J]. Immunol Rev, 2014,257(1): 107-126. DOI: 10. Ill 1/imr. 12131.
14. MULLER T, UHEREK C, MAKI G, et al. Expression of a GD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells [J]. Cancer Immunol Immunother,2008,57(3):411-423. DOI: 10. 1007/s00262-007-0383-3.
15. BOISSEL L, BETANGUR M, LU W, et al. Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens [J]. Leuk Lymphoma, 2012,53(5): 958-965. DOI: 10.3109/10428194. 2011.634048.
16. BOISSEL L, BETANGUR-BOISSEL M, LU W, et al. Retargeting NK-92 cells by means of CD19' and CD20'specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity [J]. Oncoimmunology, 2013,2(10):e26527. DOI: 10. 4161/onci. 26527.
17. + aggressive B-cell non-hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice [J]. Cancer Immunol Res, 2015, 3(4): 333-344. DOI: 10. 1158/2326-6066. CIR-14-0114.
18. BOISSEL L, BETANGUR M, WELS W S, et al. Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of GLL cells [J]. Leuk Res, 2009, 33(9): 1255-1259. DOI: 10. 1016/j. leukres. 2008. 11. 024.
19. IMAI C, IWAMOTO S, GAMPANA D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells [J]. Blood, 2005, 106 (1): 376-383. DOI: 10. 1182/blood-2004-124797.
20. ALTVATER B, LANDMEIER S, PSGHERER S, et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells [J]. Clin Cancer Res,2009,15(15): 4857-4866. DOI: 10. 1158/1078-0432. GCR-08-2810.
21. LI L, LIU L N, FELLER S, et al. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-vi-ral method [J]. Cancer Gene Ther, 2010, 17 (3): 147-154. DOI: 10. 1038/cgt. 2009. 61.
22. UHEREK G, TONN T, UHEREK B, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction [J]. Blood, 2002,100(4): 1265-1273. PMID: 12149207.
23. LIU H, YANG B, SUN T, et al. Specific growth inhibition of ErbB2 expressing human breast cancer cells by genetically modified NK92 cells [J]. Oncol Rep,2015,33(1): 95-102. DOI: 10. 3892/or. 2014.3548.
24. SGHONFELD K, SAHM C, ZHANG G, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor [J]. Mol Ther, 2015,23(2): 330-338. DOI: 10. 1038/mt. 2014. 219.
25. KRUSCHINSKI A, MOOSMANN A, POSGHKE I, et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas [J]. Proc Natl Acad Sci USA, 2008,105 (45): 17481-17486. DOI: 10. 1073/pnas. 0804788105.
26. ESSER R, MULLER T, STEFES D, et al. NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin [J]. J Cell Mol Med, 2012,16(3): 569-581. DOI: 10. 1111 /j. 1582-4934.2011.01343.x.
27. JIANG H, ZHANG W, SHANG P, et al. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells [J]. Mol Oncol, 2014, 8(2): 297-310. DOI: 10. 1016/j. molonc. 2013. 12.001.
28. OBEROI P, JABULOWSKY R A, BAHR-MAHMUD H, et al. EGFR-targeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells [J]. PLoSONE, 2013,8(4): e61267. DOI: 10. 1371/journal, pone. 0061267.
29. OBEROI P, WELS W S. Arming NK cells with enhanced antitumor activity: GARs and beyond [J]. Oncoimmunology, 2013. 2 (8): e25220. DOI: 10.4161/onci. 25220.
30. ZHANG G, LIU R, ZHU X, et al. Retargeting NK-92 for antimelanoma activity by a TGR-like single-domain antibody [J]. Immunol Cell Biol, 2013, 91 (10): 615-24. DOI: 10. 1038/icb. 2013.45.
31. VIVIER E, TOMASETL O E, BARATIN M, et al. Functions of natural killer cells [J]. Nat Immunol, 2008, 9(5): 503-510. DOI: 10. 1038/nil582.
32. TASSEV D V, CHENG M, CHEUNG N K. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor [J]. Cancer Gene Ther, 2012, 19(2): 84-100. DOI: 10. 1038/cgt. 2011.66.
33. TOPFER K, CARTELLIERI M, MICHEN S, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy [J]. J Immunol. 2015,194(7): 3201-3212. DOI: 10. 4049/jimmunol. 1400330.
34. SADELAIN M, BRENTJENS R, RIVIERE I. The basic principles of chimeric antigen receptor design [J]. Cancer Discov, 2013, 3 (4):388-398. DOI: 10.1158/2159-8290. CD-12-0548.
35. IYENGAR R, HANDGRETINGER R, BAB ARIN-DORNER A, et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method [J]. Cytotherapy, 2003, 5 (6): 479 484. DOI: 10.1080/14653240310003558.
36. KOEHL U, ESSER R, ZIMMERMANN S, et al. Ex vivo expansion of highly purified NK cells for immunotherapy after haploiden-tical stem cell transplantation in children [J]. Klin Padiatr, 2005,217(6): 345-350. DOI: 10. 1055/s-2005-872520.
37. SUTLU T, STELLAN B, GILLJAM M, et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor [J]. Cytotherapy, 2010, 12(8): 1044-1055. DOI: 10. 3109/14653249.2010.504770.
38. LEUNG S O, GAO K, WANG G Y, et al. Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody [J]. MAbs, 2015,7 (1): 66-76. DOI: 10.4161/19420862.2014.985519.
39. LEUNG W. Use of NK cell activity in cure by transplant [J]. Br J Haematol, 2011,155(1): 14-29. DOI: 10. 1111/j. 1365-2141. 2011.08823.x.
40. KOEPSELL S A, MILLER J S, MCKENNA D H Jr. Natural killer cells: a review of manufacturing and clinical utility [J]. Transfusion, 2013, 53 (2): 404-410. DOI: 10. 1111/j. 1537-2995.2012.03724.x.
41. MCKENNA D H Jr, SUMSTAD D, BOSTROM N, et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience [J]. Transfusion, 2007, 47(3): 520-528. DOI: 10. 1111/j. 1537-2995. 2006.01145.x.
42. CAROSELLA E D, PAUL P, MOREAU P, et al. HLA-G and HLA-E: fundamental and pathophysiological aspects [J]. Immunol Today, 2000, 21 (11): 532-534. PMID: 11186460.
43. ALIGI E. IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers [J]. Curr Opin Mol Ther, 2010, 12 (6): 724-733. PMID: 21154164.
44. ROMAGNE F, ANDRE P, SPEE P, et al. Preclinical characterization of 1-7 F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells [J]. Blood, 2009,114(13): 2667-2677. DOI: 10. 1182/blood-2009-02-206532.
45. CHANG Y H, CONNOLLY J, SHIMASAKI N, et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells [J]. Cancer Res, 2013,73(6): 1777-1786. DOI: 10. 1158/0008-5472. CAN-12-3558.
46. GELLER M A, COOLEY S, JUDSON P L, et al. A phase H study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer [J]. Cytotherapy, 2011, 13 (1): 98-107. DOI: 10.3109/14653249.2010.515582.
47. SPANHOLTZ J, PREIJERS F, TORDOIR M, et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process [J]. PLoS ONE, 2011,6(6): e20740. DOI: 10.1371/ journal, pone. 0020740.
48. JENA B, MO YES J S, HULS H, et al. Driving CAR-based T-cell therapy to success [J]. Curr Hematol Malig Rep, 2014, 9(1): 50-56. DOI: 10. 1007/sl 1899-013-0197-7.
49. MAKI G, KLINGEMANN H G, MARTINSON J A, et al. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92 [J]. J Hematother Stem Cell Res, 2001, 10(3): 369-383. DOI: 10.1089/152581601750288975.
50. ROMANSKI A, BUG G, BECKER S, et al. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia [J]. Exp Hematol, 2005, 33(3): 344-352. DOI: 10. 1016/j. exphem. 2004. 11. 006.
51. TONN T, SCHWABE D, KLINGEMANN H G, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92 [J]. Cytotherapy, 2013,15(12): 1563-1570. DOI: 10. 1016/j. jcyt. 2013. 06. 017.
52. MACLEOD R A, NAGEL S, KAUFMANN M, et al. Multicolor-FISH analysis of a natural killer cell line (NK-92) [J]. Leuk Res, 2002,26(11): 1027-1033. PMID: 12363472.
53. UPHOFF C C, DENKMANN S A, STEUBE K G, et al. Detection of EBV, HBV, HCV, HIV-1, HTLV-I and-II, and SMRV in human and other primate cell lines [J]. J Biomed Biotechnol, 2010,2010:904767. DOI: 10.1155/2010/904767.
54. RADZIEWICZ H, IBEGBU G G, FERNANDEZ M L, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression [J]. J Virol,2007,81(6): 2545-2553. DOI: 10. 1128/JVI. 02021-06.
55. SAHM G, SGHONFELD K, WELS W S. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor [J]. Cancer Immunol Immunother, 2012, 61 (9): 1451-1461. DOI: 10. 1007/s00262-012-1212-x.
56. GHU J, DENG Y, BENSON D M, et al. GS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma [J]. Leukemia, 2014,28(4): 917-927. DOI: 10.1038/ leu. 2013. 279.
57. WOLL P S, GRZYWAGZ B, TIAN X, et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity [J]. Blood, 2009,113(24): 6094-6101. DOI: 10. 1182/blood-2008-06-165225.
58. NI Z, KNORR D A, GLOUSER G L, et al. Human pluripotent stem cells produce natural killer cells that mediate anti-HIV-1 activity by utilizing diverse cellular mechanisms [J]. J Virol, 2011,85(l):43-50. DOI: 10. 1128/JVI. 01774-10.
59. NI Z, KNORR D A, KAUFMAN D S. Hematopoietic and nature killer cell development from human pluripotent stem cells [J]. Methods Mol Biol, 2013, 1029: 3341. DOI: 10. 1007/978-1-62703-478-4_3.
60. EGUIZABAL C, ZENARRUZABEITIA O, MONGE J, et al. Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective [J]. Front Immunol, 2014, 5: 439. DOI: 10. 3389/fimmu. 2014. 00439.
61. WOLL PS, MARTIN G H, MILLER J S, et al. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity [J]. J Immunol,2005,175(8): 5095-5103. PMID: 16210613.
62. KNORR DA, NI Z, HERMANSON D, et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy [J]. Stem Cells Transi Med, 2013,2(4): 274-283. DOI: 10. 5966/sctm. 2012-0084.
63. NI Z, KNORR D A, BENDZICK L, et al. Expression of chimeric receptor CD4zeta by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo [J]. Stem Cells, 2014,32 (4): 1021-1031. DOI: 10. 1002/stem. 1611.
64. SHAH N, MARTIN-ANTONIO B, YANG H, et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity [J]. PLoS ONE, 2013, 8(10): e76781. DOI: 10. 1371/journal, pone. 0076781.
65. DENMAN G J, SENYUKOV V V, SOMANCHI S S, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells [J]. PLoS ONE, 2012, 7(1): e30264. DOI: 10. 1371/journal, pone. 0030264.
66. SHIMASAKI N, FUJISAKI H, GHO D, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells a-gainst B-cell malignancies [J]. Cytotherapy, 2012,14(7): 830-840. DOI: 10.3109/14653249.2012.671519.
67. WANG G P, GARRIGUE A, GIUFFI A, et al. DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer [J]. Nucleic Acids Res, 2008,36(9): e49. DOI: 10. 1093/nar/gknl 25.
68. HU W S, PATHAK V K. Design of retroviral vectors and helper cells for gene therapy [J]. Pharmacol Rev, 2000,52(4): 493-511. PMID: 11121508.
69. DAVILA M L, KLOSS C G, GUNSET G, et al. CD19 CAR-targe-ted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia [J]. PLoS ONE, 2013, 8(4): e61338. DOI: 10.1371/ journal, pone. 0061338.
70. KAKARLA S, CHOW K K, MATA M, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stro-ma [J]. Mol Ther, 2013, 21(8): 1611-1620. DOI: 10.1038/ mt. 2013. 110.
71. KARO J M, SUN J C. Novel molecular mechanism for generating NK-cell fitness and memory [J]. Eur J Immunol, 2015, 45(7): 1906-1915. DOI: 10. 1002/eji. 201445339.